Positive expiratory pressure (PEP) devices are widely used in clinical settings, yet the performance characteristics of these devices remain relatively unknown. This study compared the performance characteristics of 6 airway clearance devices by varying resistance and flow.
METHODS:
Mean PEP, peak PEP, oscillation frequency, and amplitude PEP of the Flutter, Pari PEP S, Acapella Choice, Acapella DM, Acapella DH, and Aerobika devices were obtained across flows of 5, 10, 15, 20, 25 and 30 L/min and at low, medium, and high resistance using an experimental apparatus custom-built for this bench study.
RESULTS:
Performance characteristics of the devices differed across flows and resistance settings (device × flow/resistance interaction; P < .001). At a fixed resistance, increasing flows increased mean PEP produced by the Acapella Choice, Acapella DH, Aerobika, and Pari PEP S. Increasing flow resulted in minimal change in mean PEP produced by the Flutter and Acapella DM. Increasing flow increased peak PEP and amplitude PEP produced by all devices except the Acapella DH and Acapella Choice. Increasing flow maintained or increased oscillation frequency for all devices except the Flutter. At a fixed flow, increasing resistance increased mean PEP produced by all devices except the Acapella Choice. Increasing resistance increased peak PEP produced by the Acapella DM, Aerobika, and Pari PEP S but resulted in minimal change in peak PEP for the Flutter and Acapella Choice. Increasing resistance either maintained or increased oscillation frequency for all devices. Amplitude PEP was either maintained or increased during oscillations when increasing resistance for all devices except the Flutter.
CONCLUSIONS:
PEP devices produced small but statistically significant variations in performance characteristics across a range of flows and resistance settings. There appear to be flow-dependent and non–flow-dependent devices. Varying flow or resistance typically maintained or increased the production of mean, peak, and amplitude PEP and oscillation frequency.
KnowlesM, BoucherR. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest, 2002; 109(5):571–577.
2.
MöllerW, HäußingerK, Ziegler-HeitbrockL, HeyderJ. Mucociliary and long-term particle clearance in airways of patients with immotile cilia. Respir Res, 2006; 7(1):10.
3.
HauberH, FoleyS, HamidQ. Mucin overproduction in chronic inflammatory lung disease. Can Respir J, 2006; 13(6):327–335.
4.
MiravitllesM, CalleM, Alvarez-GutierrezF, GobarttE, LópezF, MartínA. Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease. Qual Life Res, 2006; 15(3):471–480.
5.
CorhayJ, VinckenW, SchlesserM, BossuytP, ImschootJ. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. Int J Clin Pract, 2013; 67(12):1294–1301.
6.
BurgelP, Nesme-MeyerP, ChanezP, CaillaudD, CarréP, PerezT, RocheN. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest, 2009; 135(4):975–982.
7.
RabinHR, ButlerSM, WohlMB, GellerDE, ColinAA, SchidlowDV, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol, 2004; 37(5):400–406.
8.
Martínez-GarcíaM, Soler-CatalunaJ, Perpiná-TorderaM, Román-SánchezP, SorianoJ. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest, 2007; 132(5):1565–1572.
9.
LoebingerM, WellsA, HansellD, ChinyanganyaN, DevarajA, MeisterM, WilsonR. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J, 2009; 34(4):843–849.
10.
MuñozG, de GraciaJ, BuxóM, AlvarezA, VendrellM. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. Eur Respir J, 2018; 51(1):1701926.
11.
FigueiredoP, ZinW, GuimarãesF. Flutter valve improves respiratory mechanics and sputum production in patients with bronchiectasis. Physiother Res Int, 2012; 17(1):12–20.
12.
TambascioJ, de SouzaL, LisboaR, Rita de CássiaV, de SouzaH, GastaldiA. The influence of Flutter® VRP1 components on mucus transport of patients with bronchiectasis. Respir Med, 2011; 105(9):1316–1321.
NicoliniA, MascardiV, GrecchiB, Ferrari-BravoM, BanfiP, BarlasciniC. Comparison of effectiveness of temporary positive expiratory pressure versus oscillatory positive expiratory pressure in severe COPD patients. Clin Respir J, 2018; 12(3):1274–1282.
15.
FaragTS, MariamE-S. Utility of vest high frequency chest wall oscillation device versus flutter device in acute exacerbation of chronic obstructive pulmonary disease. Int J Res Med Sci, 2017; 6(1):1–9.
16.
MurrayM, PentlandJ, HillA. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J, 2009; 34(5):1086–1092.
17.
YangIA, BrownJL, GeorgeJ, JenkinsS, McDonaldCF, McDonaldV, et al. The COPD-X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease 2018, version 2.53. https://copdx.org.au/wp-content/uploads/2018/05/COPDX-V2-53-March-2018-1.pdf Accessed November 2, 2018.
18.
OsadnikC, McDonaldC, HollandA. Advances in airway clearance technologies for chronic obstructive pulmonary disease. Expert Rev Respir Med, 2013; 7(6):673–685.
19.
GrothS, StafangerG, DirksenH, AndersenJ, FalkM, KelstrupM. Positive expiratory pressure (PEP-mask) physiotherapy improves ventilation and reduces volume of trapped gas in cystic fibrosis. Bull Eur Physiopathol Respir, 1985; 21(4):339–343.
20.
OberwaldnerB, EvansJ, ZachM. Forced expirations against a variable resistance: a new chest physiotherapy method in cystic fibrosis. Pediatr Pulmonol, 1986; 2(6):358–367.
21.
DarbeeJ, OhtakeP, GrantB, CernyF. Physiologic evidence for the efficacy of positive expiratory pressure as an airway clearance technique in patients with cystic fibrosis. Phys Ther, 2004; 84(6):524–537.
22.
McIlwaineP, WongL, PeacockD, DavidsonA. Long-term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy in the treatment of cystic fibrosis. J Pediatr, 2001; 138(6):845–850.
23.
MyersT. Positive expiratory pressure and oscillatory positive expiratory pressure therapies. Respir Care, 2007; 52(10):1308–1327.
24.
LeeA, BurgeA, HollandA. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev, 2015;(5):CD011699.
25.
AndersenJ, QvistJ, KannT. Recruiting collapsed lung through collateral channels with positive end-expiratory pressure. Scand J Respir Dis, 1979; 60(5):260–266.
26.
AppE, KieselmannR, ReinhardtD, LindemannH, DasguptaB, KingM, BrandP. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage. Chest, 1998; 114(1):171–177.
27.
LeeA, WilliamsonH, LorensiniS, SpencerL. The effects of oscillating positive expiratory pressure therapy in adults with stable non-cystic fibrosis bronchiectasis: a systematic review. Chron Respir Dis, 2015; 12(1):36–46.
28.
AlvesL, PittaF, BrunettoA. Performance analysis of the Flutter VRP1 under different flows and angles. Respir Care, 2008; 53(3):316–323.
29.
MuellerG, Bersch-PoradaI, Koch-BornerS, RaabA, JonkerM, BaumbergerM, MichelF. Laboratory evaluation of four different devices for secretion mobilization: Acapella Choice, Green and Blue versus water bottle. Respir Care, 2014; 59(5):673–677.
30.
ChilversM, RutmanA, O'CallaghanC. Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults. Thorax, 2003; 58(4):333–338.
31.
YagerJ, EllmanH, DulfanoM. Human ciliary beat frequency at three levels of the tracheobronchial tree. Am Rev Respir Dis, 1980; 121(4):661–665.
32.
ZhangL, HanD, WangH, ZhouB, SandersonM. Measurement of respiratory ciliary beat frequency quantified with high-speed digital microscopy. Zhonghua Er Bi Yan Hou Ke Za Zhi, 2004; 39(7):433–437.
33.
PattersonJ, HewittO, KentL, BradburyI, ElbornJ, BradleyJ. Acapella® versus usual airway clearance during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis, 2007; 4(2):67–74.
34.
CeglaU, RetzowA. Physical therapy with VRP1 in chronic obstructive respiratory tract diseases-results of a multicenter comparative study. Pneumologie, 1993; 47(11):636–639.
35.
de LimaL, DuarteJ, Lepore NetoF, AbeP, GastaldiA. Mechanical evaluation of a respiratory device. Med Eng Phys, 2005; 27:181–187.
36.
KingM, PhillipsD, GrossD, VartianV, ChangH, ZidulkaA. Enhanced tracehal mucus clearance with high frequency chest wall compression. Am Rev Respir Dis, 1983; 128(3):511–515.
37.
ChangA, BellS, TorzilloP, KingP, MaguireG, ByrnesC, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust, 2015; 202(3):130.
38.
ButtonB, WilsonC, DenticeR, CoxN, MiddletonA, TannenbaumE, et al. Physiotherapy for cystic fibrosis in Australia and New Zealand: a clinical practice guideline. Respirology, 2016; 21(4):656–667.
39.
NICE clinical guidelines: Obstructive pulmonary disease in over 16s: diagnosis and management 2010:CG101.
40.
PasteurM, BiltonD, HillA. British Thoracic Society guideline for non-CF bronchiectasis. Thorax, 2010; 65(1):1–58.
41.
PolverinoE, GoeminneP, McDonnellM, AlibertiS, MarshallS, LoebingerM, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J, 2017; 50(3):1700629.
42.
ElkinsM, JonesA, van der SchansC. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev, 2004; 1:CD003147.
43.
McIlwaineP, ButtonB, DwanK. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev, 2015; 1:CD003147.
44.
Van FleetH, DunnD, McNinchN, VolskoT. Evaluation of functional characteristics of 4 oscillatory positive pressure devices in a simulated cystic fibrosis model. Respir Care, 2017; 62(4):451–458.
45.
BerlinskiA. In-vitro evaluation of positive expiratory pressure devices attached to nebulizers. Respir Care, 2014; 59(2):216–222.
46.
RandS, AuroraP, MainE. PEP therapy in secretion management. Hosp Healthc Eur, 2015:113–116.
47.
VolskoT, DiFioreJ, ChatburnR. Performance comparison of two oscillating positive expiratory pressure devices: Acapella versus Flutter. Respir Care, 2003; 48(2):124–130.
48.
PattersonJ, BradleyJ, HewittO, BradburyI, ElbornJ. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques versus Acapella®. Respiration, 2005; 72(3):239–242.
49.
SvenningsenS, PaulinG, SheikhK, GuoF, HasanyA, KirbyM, et al. Oscillatory positive expiratory pressure in chronic obstructive pulmonary disease. COPD, 2016; 13(1):66–74.
50.
dos SantosA, GuimaraesR, de CarvalhoE, GastaldiA. Mechanical behaviours of Flutter VRP1, Shaker and Acapella Devices. Respir Care, 2013; 58(2):298–304.
51.
LindemannH. The value of physical therapy with VRP 1-Desitin (“Flutter”). Pneumologie, 1992; 46:626–630.
52.
Alves SilvaCE, SantosJ, JansenJ, de MeloP. Laboratory evaluation of the Acapella device: pressure characteristics under different conditions, and a software tool to optimize its practical use. Respir Care, 2009; 54(11):1480–1487.
53.
BrooksD, NewboldE, KozarL, RiveraM. The flutter device and expiratory pressures. J Cardiopulm Rehabil Prev, 2002; 22(1):53–57.
54.
AlvesC, NunesL, MeloP. Mechanical analysis of an oscillatory positive expiratory pressure device used in respiratory rehabilitation. Conf Proc IEEE Eng Med Biol Soc, 2010; 2477–2480.
55.
SuggettJ, MeyerA, CostellaS, MortonR, MitchellJ. Assessment of oscillating positive expiratory pressure (OPEP) devices by means of adult expiratory waveforms: a laboratory study. Am J Respir Crit Care Med, 2014; 189:A3036.
56.
PursleyD. Analysis of three oscillating positive expiratory pressure devices during simulated breathing. Respir Ther, 2017; 12(1):52–56.
57.
FalkM, KelstrupM, AndersenJ, KinoshitaT, FalkP, StøvringS, GothenI. Improving the ketchup bottle method with positive expiratory pressure, PEP, in cystic fibrosis. Eur J Respir Dis, 1984; 65(6):423–432.
